Necrostatin-1 (Nec-1)

Katalognr.S8037 Batch:S803704

Skriv ut

Tekniska data

Formel

C13H13N3OS

Molekylvikt 259.33 CAS-nr. 4311-88-0
Löslighet (25°C)* In vitro DMSO 52 mg/mL (200.51 mM)
Water Insoluble
Ethanol Insoluble
In Vivo (Tillsätt lösningsmedel till produkten individuellt och i ordning.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml betyder svårlösligt eller olösligt.
* Vänligen notera att Selleck testar lösligheten för alla förbindelser internt, och den faktiska lösligheten kan skilja sig något från publicerade värden. Detta är normalt och beror på små variationer mellan olika partier.
* Rumstempererad frakt (Stabilitetstester visar att denna produkt kan fraktas utan några kylåtgärder.)

Beredning av stamlösningar

Biologisk aktivitet

Beskrivning Necrostatin-1 (Nec-1) är en specifik RIP1 (RIPK1)-hämmare och hämmar TNF-α-inducerad nekroptos med ett EC50 på 490 nM i 293T-celler. Necrostatin-1 blockerar också IDO och undertrycker autophagy och apoptosis.
Mål
IDO RIP1
(293T cells)
490 nM(EC50)
In vitro

Necrostatin-1 (1-100 μM) inhibits the autophosphorylation of overexpressed and endogenous RIP1.It is found RIP1 is the primary cellular target responsible for the antinecroptosis activity of this compound.

This chemical efficiently suppresses necroptotic cell death triggered by an array of stimuli in a variety of cell types. It, previously identified as small-molecule inhibitor of necroptosis, inhibits RIP kinase-induced necroptosis and inhibits TNF-α-induced necroptosis in jurkat cells with EC50 of 490 nM.

In Vivo

Necrostatin-1 (Nec-1) is a specific small molecule inhibitor of receptor-interacting protein kinase 1 (RIPK1) that specifically inhibits phosphorylation of this compound.

Egenskaper Ett kraftfullt verktyg för att karakterisera rollen av necroptosis med karakteriserat primärt mål.

Protokoll (från referens)

Kinasanalys:

[1]

  • RIP kinase-analys

    Fosforylering av RIP1 kräver dess kinasaktivitet. Uttryckskonstruktioner av FLAG-taggat vildtyp (WT) eller en kinas-inaktiv punktmutant av RIP1 (K45M) transfekteras in i 293T-celler och RIP1-kinasanalys utförs enligt beskrivningen i metodavsnittet i närvaro av [γ-32P]ATP under 30 minuter vid 30℃. Proverna utsätts för SDS-PAGE och RIP1-bandet visualiseras genom autoradiografi. De relativa intensiteterna för radioaktiva band kvantifieras och visas (som kvot) i denna och alla andra autoradiografer. Parallellt med kinasreaktionerna utsätts ett prov av kulor för western blot-analys med användning av anti-RIP1-antikropp för att säkerställa lika proteinmängder i kinasreaktionerna.

Cellanalys:

[2]

  • Cellinjer

    Jurkat, BALB/c 3T3, SV40-transformed MEF, L929

  • Koncentrationer

    0.01-100 μM

  • Inkubationstid

    --

  • Metod

    Cells are seeded in 96-well plates (white plates for luminescent assays; black plates for fluorescent assays; clear plates for MTT assay) at the density of 5,000-10,000 cells per well for adherent cells or 20,000-50,000 cells per well for suspension cells in 100 μl of the appropriate phenol red-free media. After incubation, we determined cell viability using one of the following methods. For the ATP assay, we used luminescence-based commercial kits and analyzed luminescence using a Wallac Victor II plate reader. For Sytox assay, we incubated cells with 1 μM Sytox Green reagent for 30 min at 37℃, and then performed fluorescent reading. Subsequently, we added 5 μl of 20% Triton X-100 solution into each well to produce maximal lysis and incubated cells for 1 h at 37℃, then performed the second reading. We calculated the ratio of values before and after Triton treatment and normalized it to the relevant controls not subjected to cytotoxic stimuli, as indicated in figure legends. For the MTT assay, we used the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit. For PI exclusion assays, we added 2 μg/ml PI into the medium and immediately analyzed samples using FACSCalibur. For PI-annexin V assay we used the ApoAlert Annexin V-EGFP Apoptosis Kit. For DioC6 staining, we incubated cells with 40 nM DiOC6 for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. For ROS analysis, we incubated cells with 5 μM dihydroethidium for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. EM analyses are performed at the Harvard Medical School EM facility. We acquired bright-field images of the cells using an Axiovert 200 microscope.

Djurstudie:

[3]

  • Djurmodeller

    Male C57BL/6 mice

  • Doseringar

    0.0468 mg/Kg

  • Administrering

    i.a.

Referenser

  • http://www.ncbi.nlm.nih.gov/pubmed/?term=18408713
  • http://www.ncbi.nlm.nih.gov/pubmed/?term=16408008
  • https://pubmed.ncbi.nlm.nih.gov/30542285/

Kundvalidering av produkt

Cytosolic extracts or nuclear extracts were examined by Western blot analysis using Abs against p105/p50, p100/p52 and phospho-p65. Solid arrowhead indicates a non-specific band. A nuclear marker, PARP, and cytosolic marker, b-tubulin, were used to assess the purity of each fraction.

Data från [ , , J Cell Mol Med, 2015, 19(5): 1042-54 ]

HCT16 was treated with or without AMDE-1 (2.5 μM), zVAD (20 μM), and/or necrostatin-1 (necro, 40 μM) for 48 hours. Cell death was measured. Values represent means ± SD from three independent experiments.

Data från [ , , PLoS One, 2015, 10(3): e0122083 ]

The influence of MAPK/NF-kB pathways and TNF-α/IL-8 factors on the survival of Beas-2B cells irradiated with 0.5 Gyα-particles. (A) The irradiated cells had no further co-culture with U937 cells. (B) The irradiated Beas-2B cells were further co-cultured with U937 cells for 24 h after irradiation. In some experiments, Beas-2B cells were pretreated with 10 μM of U0126, SB203580, or necrostatin-1 for 1 h before irradiation, U937 cells were pretreated with 10 μM BAY 11-7082 1 h prior to cell co-culture, or 1 μg/ml anti-TNF-a antibody, 2 μg/ml anti-IL-8 antibody, 40 nM SB225002 were added to the medium in the cell co-culture period. ***P < 0.001compared with the non-irradiation control. #P < 0.05 ##P < 0.01 compared with cor-responding  α-irradiated cells.

Data från [ , , Mutation Research, 2016, 789:1-8. ]

Sellecks Necrostatin-1 (Nec-1) Har citerats av 329 Publikationer

Peroxisome-derived and liver-specific hydroxyacid oxidase 1-mediated hydrogen peroxide promotes ferroptosis by augmenting peroxisomal ROS [ J Adv Res, 2026, S2090-1232(26)00342-5] PubMed: 41990971
Opposing roles of DGAT-mediated lipid droplet biogenesis in the regulation of ferroptosis sensitivity [ FEBS J, 2026, 10.1111/febs.70467] PubMed: 41729026
Andrographolide-induced PANoptosis underlies its multiple organ toxicity in mice [ Toxicol Appl Pharmacol, 2026, 507:117682] PubMed: 41371369
Soluble tissue factor generated by necroptosis-triggered shedding is responsible for thrombosis [ Cell Res, 2025, 10.1038/s41422-025-01167-8] PubMed: 40940518
The noncanonical function of liver-type phosphofructokinase potentiates the efficacy of HDAC inhibitors in cancer [ Signal Transduct Target Ther, 2025, 10(1):341] PubMed: 41083431
LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma [ Cancer Discov, 2025, 10.1158/2159-8290.CD-24-1317] PubMed: 39919290
AAK1 activation-mediated iron trafficking drives ferroptotic cell death [ Nat Commun, 2025, 17(1):819] PubMed: 41407700
Ferroptosis-activating metabolite acrolein antagonizes necroptosis and anti-cancer therapeutics [ Nat Commun, 2025, 16(1):4919] PubMed: 40425585
Harnessing the FGFR2/NF2/YAP signaling-dependent necroptosis to develop an FGFR2/IL-8 dual blockade therapeutic strategy [ Nat Commun, 2025, 16(1):4128] PubMed: 40319089
Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis [ Cell Rep Med, 2025, 6(2):101928] PubMed: 39879992

RETURPOLICY
Selleck Chemicals villkorslösa returpolicy säkerställer en smidig online-shoppingupplevelse för våra kunder. Om du på något sätt är missnöjd med ditt köp kan du returnera artikeln/artiklarna inom 7 dagar efter mottagandet. I händelse av produktkvalitetsproblem, antingen protokollrelaterade eller produktrelaterade problem, kan du returnera artikeln/artiklarna inom 365 dagar från det ursprungliga köpdatumet. Vänligen följ instruktionerna nedan vid retur av produkter.

FRAKT OCH FÖRVARING
Sellecks produkter transporteras i rumstemperatur. Om du tar emot produkten i rumstemperatur kan du vara trygg; Sellecks kvalitetskontrollavdelning har utfört experiment för att verifiera att placering i normal temperatur under en månad inte påverkar den biologiska aktiviteten hos pulverprodukter. Efter insamling ska produkten förvaras i enlighet med de krav som beskrivs i databladet. De flesta av Sellecks produkter är stabila under de rekommenderade förhållandena.

EJ AVSEDD FÖR ANVÄNDNING PÅ MÄNNISKOR, INOM VETERINÄRDIAGNOSTIK ELLER FÖR TERAPEUTISKT BRUK.